Operator: Good day, everyone. Welcome to BeOne Medicine’s Q3 2025 Earnings Call Webcast.
[Operator Instructions] After the speakers’ remarks, there will be a question-and-answer session. At this time, I would like to turn the call over to the company.
—
**Daniel Maller:** Hello and welcome. Thanks for joining us today. I’m Dan Maller, Head of Investor Relations at BeOne Medicines.
Before we begin, please note that you can find additional materials, including a replay of today’s webcast and presentation, on the Investor Relations section of our website at ir.beonemedicines.com.
I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company’s future prospects and business strategy. Actual results may differ materially from those indicated in the forward-looking statements due to various factors, including those risks discussed in our most recent periodic report filed with the SEC.
Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation.
Reconciliations between GAAP and non-GAAP financial measures discussed on this call are available for your reference.
https://seekingalpha.com/article/4839255-beone-medicines-ag-onc-q3-2025-earnings-call-transcript?source=feed_all_articles